Q4 2025 Management View CEO David Meeker highlighted the continued strong performance of Rhythm’s commercial teams, noting, "The BBS opportunity continues to grow at a steady rate, both in the United ...
Hosted on MSN
Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position
David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acquired hypothalamic obesity pending FDA ...
David Meeker, MD, is stepping down from Cambridge, Mass.-based Sanofi Genzyme at the end of June 2017 as the company’s executive vice president and head, according to the Boston Globe. 1. Bill Sibold ...
Good day, and welcome to Rhythm Pharmaceuticals Fourth Quarter and Fiscal Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results